Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Welcome back Freddieboy.
The same problem exists today that existed when you last left in that the company has a potential product in exosomes, but as yet it hasn't been realized.
There was an RNS on exosomes and proof of concept invitro and that the next stage of delivery of drugs to specific parts of a body in large enough quantities to be effective was going to begin.
There was going to be an announcement at a conference and then it suddenly all went quiet, and nobody knows why.
This where we all are now.
P.S, I think the company runs out of money in April. Good luck.
Welcome back Fred. There’s been successor optimists but none with your dispositional level, altho with similar levels of prophetic skills. Since you left we’ve also lost your nemesis, Purpleachy, so will your return result in Purps resurrection too?
I’m sure the optimists will give you a heads up, and Purp, if he/she is around will no doubt provide appropriate checks and balances.
Your return will also no doubt once again raise the question, has Fred and Mr Woodford ever been seen in the same room together 😀Anyway good to hear from you. Good luck if you ultimately invest. There’s a lot of us with fingers and everything else crossed.
I sold out a few years ago when we found out the stroke treatment couldn't be verified as due to stem cell treatment or the body healing itself.
As for the Retinitis Pigmentosa and using stem cell tails to deliver cancer treatments though the blood barrier membrane, it was in its infancy....John Sindon was in charge a Mr Hunt finance director.
Times moved on and have no idea what they are cooking up now and how close the boil they are. One things for certain the sp appears to have taken a hammering and I could consider reinvesting.
Would one of you kind gents/Ladies bring me up to speed on the current pipeline and any treatments showing short term potential....by short I don't mean a month away as infinite months is a short term target for Reneuron.
I'd prefer to hear what investors are expecting as against the company Bull..
Sincerely Fred
Makes sense, thanks!
Because the trade price sits closer to the bid than the ask .
Pretty sure 1st 4 trades @6.24 ish are buys, one of which was mine! Why are LSE listing them wrong, I wonder?
Nope. Not even a generic response. I have been entertaining some guests who are staying for a few days, so if the radio silence continues, I will follow up on Monday when I have some time to do so.
They should call this company Titanic because it sure to hell going down perhaps Atra zenica might be able to make use of some of Rene, s equipment because they don, t have clue how to use it.
LW did you get a response to your email about the conference ‘no-show’? I was wondering whether Mr Ross had run out of petty-cash for the airfare or he didn’t want to be embarrassed by questions on going belly-up, or conversely whether there’s a bailout in play?
...or someone wants in cheap?
Likely to be one the aim causalities, delists ahead
That’s what normally happens, although Mr Ross failed to get one away late last year. In recent times, retail stockholders have been offered rights issue crumbs; although thank goodness for that as my losses would be even greater!
The company is fast running out of cash, and I would suggest any deal down the track will result in a deal to take part of the Equity in exchange for cash.
You have to ask, why would RENE do an enthusiastic RNS ( re- INVIVO results ) and then not attend / present at an Exosomes Industry focused conference. We're they ever listed as definite attendee ?
It can't be that their science somehow got derailed as they did that RNS at 7.00am on the 4th Sept the day before the conference.
It does feel like something is happening in the background and I'm hoping that what ever 'it' is, that it's a positive thing.
Chester.
Yes, obviously high risk but, if it comes good, any deal could be huge.
No response so far. We can only hope that there is a positive reason for that. That word again, hope. Some interesting trades recently though, so who knows?
GLA while we wait for something more concrete than hope!
Investors are hopeful that the company's long-standing commitment to research could yield positive outcomes in the future.
While it may not be of utmost importance, it's worth noting that the 10K listed as a sell was actually a purchase
As some stock up on Bud for the weekend by selling small Rene tranches, others, as we await Mr Ross’ response to LW’s email, may be conjugating variables of what the no-show could mean? But having ruminated on potential conspiracy theories, it’s probably as simple as we couldn’t afford the airline ticket!
We are certainly on thin ice territory with trust right now.
Mr Ross, under the corporate risk of going ‘belly-up’ suggests in the Annual Report a mitigation that the Board places considerable emphasis on communication with stockholders. Given there’s still buyers out there, relying on goodness knows what, I’m not sure we should give him or his board any benefit of the doubt.
I do not have an open line, but sent an email to this end recently.
IMO, we should have been notified about any changes, even if only a reach RNS.
I will share my reply once received, although we might get an RNS now.
Not impressed, to be honest. Benefit of the doubt. For now.
For those with an open line to Mr Ross, what’s the score on the conference non-attendance, which Grizzly has highlighted?
I guess they didn't present after all? No longer on the speakerlist and the event removed from ReNeuron's website, unless I'm mistaken.
https://exosomebased-therapeutics.com/speakers/
Yep. It is indeed hopium, unless/until proven otherwise.
At least multiple insiders put their hands in their pockets with this one. Unlike so many AIM outfit BODs.
Just a waiting game now. Should not be too much longer, IMO. For good or for bad.
Still backing Iain and the team, FWIW, but not a recommendation etc. GLA.